argenx SE (ARGX) Expands Autoimmune Leadership with Vyvgart Launch

In this article, we will be taking a look at the 11 Best Performing Biotech Stocks So Far in 2025. argenx SE is one of them. argenx SE (NASDAQ:ARGX) is strengthening its leadership in autoimmune therapies with the rapid expansion of Vyvgart, its flagship antibody-based treatment. Available in both intravenous and subcutaneous forms, Vyvgart has become a cornerstone therapy for generalized myasthenia gravis (gMG) and is now extending its reach into other autoimmune diseases, including immune thrombocytopen ...